Skip to main content

Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
Molecular Cell

This review offers a practical resource to compare and contrast these technologies, guiding the investigator when and where to use this fantastic array of powerful tools.

CTD²
Nature Methods

Researchers report the BAMSurgeon tool for simulating cancer genomes and the results of 248 analyses of three in silico tumors.

CTD²
J Am Chem Soc.

Researchers report on  the discovery of a novel, small-molecule modulator of lysosomal acidification derived from diversity-oriented synthesis through high-content screening.

CTD²
Oncogene

To uncover novel mechanisms of resistance to anti-HER2 therapy in breast cancer, researchers performed a kinase open reading frame screen to identify genes that rescue HER2-amplified breast cancer cells from HER2 inhibition or suppression.

CTD²
Journal of Clinical Investigation

Researchers discuss BRAF inhibitor-resistant melanomas can be actionably classified using protein expression patterns, even without identification of the underlying genetic alteration.

CTD²
Clinical Cancer Research

New ways of suppressing KRAS gene expression and of harnessing the immune system to exploit previously unrecognized vulnerabilities in human cancers. 

CTD²
Genome Medicine

A review about 3D culture models for cancer research.

CTD²
Nature Medicine

In this reveiw authors discuss how organoid methods have the potential to herald the dawn of a new era in cancer biology investigation.

TARGET
Nature Communcations

Researchers used deep whole-exome sequencing to describe the clonal architecture and evolution of 20 pediatric B-acute lymplobastic leukaemias from diagnosis to relapse.

CTD²
Cancer Cell

Researchers conducted a large-scale functional genetic study to characterize mechanisms of resistance to ALK inhibition in ALK-dependent lung cancer cells and identified additional members of known of putative resistance drivers.